As a biomedical company dedicated to research and development of in vitro diagnostics for early cancer detection,
Since its establishment, CUBEBIO has committed itself to research and development of cancer biomarkers and products for early cancer detection.
In light of the latest trend in the in vitro diagnostics market, the global point-of-care testing (POCT) market is growing rapidly. Instead of using blood samples, cancer biomarker research using urine or saliva has been underway. In an effort to keep up with the current market trend, CUBEBIO has been focusing on research on urine-based cancer biomarkers.
As a result of this effort, we are one step closer to the commercialization of the cancer diagnostic kit and the cancer self-diagnostic device for early screening by using urine as a specimen. Through a partnership with the Union for International Cancer Control (UICC), the largest and oldest international cancer organization, we are planning to build a global network and to promote the significance of early cancer detection as well as the concept of self-diagnosis around the world.
With our unique technology and product development, we have firmly established our competitive advantages to become the world’s top company in the POCT market. Additionally, in order to secure continuous growth and future competitiveness of the company, we are expanding our investments in R&D and doing everything possible to attract outstanding laboratory personnel and to nurture talents.
CUBEBIO's most important mission is to transform a paradigm of the cancer diagnostics market. We are aiming to lead the popularization of POCT products that are accurate, fast, and easy-to-use for customers. We will strive to boost people's health and happiness. By doing so, we will become the company that our customers adore.
"We show our deepest appreciation to all our customers for your support and affection towards CUBEBIO."
we will become the world’s best company by contributing to the promotion of people’s health and happiness.”